Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

World’s Pharmaceutical Inspectorates Prepare For Post-Pandemic Remote Site Assessments

Executive Summary

US, EU, global authorities share experiences, insights, advice for industry on remote alternatives even after inspectors can resume travels.

You may also be interested in...



US FDA Explains Why Remote Interactive Evaluations Guidance Took So Long

Time taken for interagency alignment, lessons learned from foreign counterparts will increase use of remote video tours, FDA officials tell the Pink Sheet.

Remote Site Visits Will Help US FDA Keep Reviews On Track During Remainder Of Pandemic

Video facility tours expected to help clear way for timely drug and biologic approvals while COVID-19 still prevents inspections.

How The European Medicines Agency Inspected Thermo Fisher’s Florida Plant Without Leaving Europe

Contract development and manufacturing organization relied on combination of immersive mixed-reality devices to host remote inspection.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel